Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Size: 566 KB